Standard PBM Oversight Isn’t Enough to Protect Your Plan
Why One PharmD Refused to Take “No” for an Answer
October 14, 2026
Aprepitant is a drug intended for short-term use. One capsule after surgery, or three days before a round of chemotherapy treatment.
So, when Jill Sailors, PharmD and PBIRx Senior Clinical Analytical Specialist, saw an approval rule that allowed 16 capsules every 28 days, she stopped. She was only there for a prior authorization appeal review, a check on a request to cover a drug, and the claim in front of her could have been closed in minutes.
But 16 capsules every 28 days isn’t a treatment plan for a short-term drug. It’s a permission slip for months of use, for a drug designed for one time use or three alongside a chemo treatment. The FDA label specifically cautions against long-term use, along with the interactions and toxicity risks that come with it.
She raised it.
The pharmacy benefit manager (PBM) came back with a polite no: the limits were consistent with the literature.
It would have been easy to say “fair enough” and move on. Jill didn’t. She pulled the manufacturer data. She found a current member on continuous aprepitant for months. She wrote a rebuttal. When that didn’t move things, she took it to the PBM’s top clinical leaders.
Then she gave them two weeks.
Fix it, or she’d file a quality-of-care report with NCQA and a grievance with URAC, the independent bodies that accredit health plans. It wasn’t a bluff. Her case rested on the FDA label and those bodies’ own standards, which left very little to argue with.
They fixed it using Dr. Sailors’ suggestions.
Since July 1, 2026, prescriptions after surgery carry strict quantity limits, and beginning Jan 1,2027, chemo-related use has to go through an oncologist or a provider working with one. The change doesn’t stop at our clients. It covers the PBM’s entire national commercial book of business.
One flagged claim.
One number that didn’t make sense.
A rule rewritten for everyone.
If you’re an employer or plan sponsor, ask your PBM: who checks the rules that decide which drugs get approved, and how often? And if they found a problem in those rules, would they push past the first “no”?
